Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Quality System Regulations, 63834-63838 [2010-26102]
Download as PDF
63834
Federal Register / Vol. 75, No. 200 / Monday, October 18, 2010 / Notices
TABLE 1—ESTIMATES OF ANNUAL BURDEN HOURS
Frequency of
response
Instrument(s) tested
Read Invitation (Attachments 3) ..............................................
Pre-Enrollment (Attachment 6) ................................................
Enrollment Process (Attachment 7) .........................................
ASA24 (Attachments 4–1) .......................................................
ACT–24 (Attachments 4–2) .....................................................
LHQ (Attachments 4–3) ...........................................................
DHQ (Attachments 4–4) ..........................................................
Web Re-entry (Attachment 8) ..................................................
Evaluation Survey (Attachment 9) ...........................................
1.00
1.00
1.00
2.00
2.00
1.00
1.00
6.00
1.00
Totals ................................................................................
..............................
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
practical utility; (2) Evaluate the
accuracy of the agency’s estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and (4) Minimize the burden
of the collection of information on those
who are to respond, including the use
of appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact Arthur Schatzkin,
M.D., Dr.P.H, Chief, Nutritional
Epidemiology Branch, Division of
Cancer Epidemiology and Genetics,
National Cancer Institute, NIH, DHHS,
Executive Plaza South, Room 3040,
6120 Executive Blvd., EPS–MSC 7242,
Bethesda, MD 20892–7335 or call nontoll-free number 301–594–2931 or email your request, including your
address to: schatzka@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT:
mstockstill on DSKH9S0YB1PROD with NOTICES
Average time per
response
(minutes/hour)
Dated: October 12, 2010.
Vivian Horovitch-Kelley,
NCI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. 2010–26187 Filed 10–15–10; 8:45 am]
BILLING CODE 4140–01–P
VerDate Mar<15>2010
16:45 Oct 15, 2010
Jkt 223001
1/60
10/60
5/60
30/60
15/60
20/60
45/60
5/60
1/60
Number of
respondents
Annual hour
burden
(0.017)
(0.167)
(0.083)
(0.500)
(0.250)
(0.333)
(0.750)
(0.083)
(0.017)
16,667.00
2,312.00
2,288.00
1,944.00
1,944.00
1,944.00
1,944.00
1,944.00
2,288.00
278
385
191
1,944
972
648
1,458
972
38
..............................
33,275.00
6,886
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
collection of information to OMB for
review and clearance.
Food and Drug Administration
Medical Devices: Current Good
Manufacturing Practice Quality System
Regulations—21
[Docket No. FDA–2010–N–0273]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Current Good
Manufacturing Practice Quality System
Regulations
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by November
17, 2010.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or e-mailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0073. Also
include the FDA docket number found
in brackets in the heading of this
document.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Daniel Gittleson, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
5156, Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
CFR Part 820 (OMB Control Number
0910–0073)—Extension
Under section 520(f) of the Federal
Food, Drug, and Cosmetic Act (the
FD&C act) (21 U.S.C. 360j(f)), the
Secretary of the Department of Health
and Human Services has the authority
to prescribe regulations requiring that
the methods used in, and the facilities
and controls used for, the manufacture,
preproduction design validation
(including a process to assess the
performance of a device but not
including an evaluation of the safety
and effectiveness of a device), packing,
storage, and installation of a device
conform to current good manufacturing
practice (CGMP), as described in such
regulations, to assure that the device
will be safe and effective and otherwise
in compliance with the act.
The CGMP/quality system (QS)
regulation implementing authority
provided by this statutory provision is
found under part 820 (21 CFR part 820)
and sets forth basic CGMP requirements
governing the design, manufacture,
packing, labeling, storage, installation,
and servicing of all finished medical
devices intended for human use. The
authority for this regulation is covered
under sections 501, 502, 510, 513, 514,
515, 518, 519, 520, 522, 701, 704, 801,
and 803 of the FD&C act (21 U.S.C. 351,
352, 360, 360c, 360d, 360e, 360h, 360i,
360j, 360l, 371, 374, 381, and 383). The
CGMP/QS regulation includes
requirements for purchasing and service
controls, clarifies recordkeeping
requirements for device failure and
complaint investigations, clarifies
requirements for verifying/validating
production processes and process or
product changes, and clarifies
E:\FR\FM\18OCN1.SGM
18OCN1
mstockstill on DSKH9S0YB1PROD with NOTICES
Federal Register / Vol. 75, No. 200 / Monday, October 18, 2010 / Notices
requirements for product acceptance
activities quality data evaluations and
corrections of nonconforming product/
quality problems.
Requirements are compatible with
specifications in the international
standards ‘‘ISO 9001: Quality Systems
Model for Quality Assurance in Design/
Development, Production, Installation,
and Servicing.’’ The CGMP/QS
information collections will assist FDA
inspections of manufacturers for
compliance with QS requirements
encompassing design, production,
installation, and servicing processes.
Section 820.20(a) through (e) requires
management with executive
responsibility to establish, maintain,
and/or review the following topics:
(1) The quality policy, (2) the
organizational structure, (3) the quality
plan, and (4) the quality system
procedures of the organization.
Section 820.22 requires the conduct
and documentation of QS audits and reaudits. Section 820.25(b) requires the
establishment of procedures to identify
training needs and documentation of
such training.
Section 820.30(a)(1) and (b) through
(j), requires in respective order, the
establishment, maintenance, and/or
documentation of the following topics:
(1) Procedures to control design of class
III and class II devices and certain class
I devices as listed therein; (2) plans for
design and development activities and
updates; (3) procedures identifying,
documenting, and approving design
input requirements; (4) procedures
defining design output, including
acceptance criteria, and documentation
of approved records; (5) procedures for
formal review of design results and
documentation of results in the design
history file (DHF); (6) procedures for
verifying device design and
documentation of results and approvals
in the DHF; (7) procedures for validating
device design, including documentation
of results in the DHF; (8) procedures for
translating device design into
production specifications; (9)
procedures for documenting, verifying,
and validating approved design changes
before implementation of changes; and
(10) the records and references
constituting the DHF for each type of
device.
Section 820.40 requires manufacturers
to establish and maintain procedures
controlling approval and distribution of
required documents and document
changes.
Section 820.40(a) and (b) requires the
establishment and maintenance of
procedures for the review, approval,
issuance, and documentation of
VerDate Mar<15>2010
16:45 Oct 15, 2010
Jkt 223001
required records (documents) and
changes to those records.
Section 820.50(a)(1), (a)(2), (a)(3), and
(b) requires the establishment and
maintenance of procedures and
requirements to ensure service and
product quality, records of acceptable
suppliers, and purchasing data
describing specified requirements for
products and services.
Sections 820.60 and 820.65 require,
respectively, the establishment and
maintenance of procedures for
identifying all products from receipt to
distribution and for using control
numbers to track surgical implants and
life-sustaining or supporting devices
and their components.
Section 820.70(a)(1) through (a)(5), (b)
through (e), (g)(1) through (g)(3), (h), and
(i) requires the establishment,
maintenance, and/or documentation of
the following topics: (1) Process control
procedures; (2) procedures for verifying
or validating changes to specification,
method, process, or procedure; (3)
procedures to control environmental
conditions and inspection result
records; (4) requirements for personnel
hygiene; (5) procedures for preventing
contamination of equipment and
products; (6) equipment adjustment,
cleaning, and maintenance schedules;
(7) equipment inspection records; (8)
equipment tolerance postings,
procedures for utilizing manufacturing
materials expected to have an adverse
effect on product quality; and (9)
validation protocols and validation
records for computer software and
software changes.
Sections 820.72(a), (b)(1), and (b)(2)
and 820.75(a) through (c) require,
respectively, the establishment,
maintenance, and/or documentation of
the following topics: (1) Equipment
calibration and inspection procedures;
(2) national, international or in-house
calibration standards; (3) records that
identify calibrated equipment and next
calibration dates; (4) validation
procedures and validation results for
processes not verifiable by inspections
and tests; (5) procedures for keeping
validated processes within specified
limits; (6) records for monitoring and
controlling validated processes; and (7)
records of the results of revalidation
where necessitated by process changes
or deviations.
Sections 820.80(a) through (e) and
820.86, respectively, require the
establishment, maintenance, and/or
documentation of the following topics:
(1) Procedures for incoming acceptance
by inspection, test, or other verification;
(2) procedures for ensuring that in
process products meet specified
requirements and the control of product
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
63835
until inspection and tests are
completed; (3) procedures for, and
records that show, incoming acceptance
or rejection is conducted by inspections,
tests or other verifications; (4)
procedures for, and records that show,
finished devices meet acceptance
criteria and are not distributed until
device master record (DMR) activities
are completed; (5) records in the device
history record (DHR) showing
acceptance dates, results, and
equipment used; and (6) the acceptance/
rejection identification of products from
receipt to installation and servicing.
Sections 820.90(a), (b)(1), and (b)(2)
and 820.100 require, respectively, the
establishment, maintenance and/or
documentation of the following topics:
(1) Procedures for identifying,
recording, evaluating, and disposing of
nonconforming product; (2) procedures
for reviewing and recording concessions
made for, and disposition of,
nonconforming product; (3) procedures
for reworking products, evaluating
possible adverse rework effect and
recording results in the DHR; (4)
procedures and requirements for
corrective and preventive actions,
including analysis, investigation,
identification and review of data,
records, causes, and results; and (5)
records for all corrective and preventive
action activities.
Section 820.100(a)(1) through (a)(7)
states that procedures and requirements
shall be established and maintained for
corrective/preventive actions, including
the following: (1) Analysis of data from
process, work, quality, servicing
records; investigation of
nonconformance causes; (2)
identification of corrections and their
effectiveness; (3) recording of changes
made; and (4) appropriate distribution
and managerial review of corrective and
preventive action information. Section
820.120 states that manufacturers shall
establish/maintain procedures to control
labeling storage/application; and
examination/release for storage and use,
and document those procedures.
Sections 820.120(b) and (d), 820.130,
820.140, 820.150(a) and (b), 820.160(a)
and (b), and 820.170(a) and (b),
respectively, require the establishment,
maintenance, and/or documentation of
following topics: (1) Procedures for
controlling and recording the storage,
examination, release, and use of
labeling; (2) the filing of labels/labeling
used in the DHR; (3) procedures for
controlling product storage areas and
receipt/dispatch authorizations; (4)
procedures controlling the release of
products for distribution; (5)
distribution records that identify
consignee, product, date, and control
E:\FR\FM\18OCN1.SGM
18OCN1
mstockstill on DSKH9S0YB1PROD with NOTICES
63836
Federal Register / Vol. 75, No. 200 / Monday, October 18, 2010 / Notices
numbers; and (6) instructions,
inspection and test procedures that are
made available, and the recording of
results for devices requiring installation.
Sections 820.180(b) and (c),
820.181(a) through (e), 820.184(a)
through (f), and 820.186 require,
respectively, the maintenance of records
that are: (1) Retained at prescribed
site(s), made readily available and
accessible to FDA and retained for the
device’s life expectancy or for 2 years;
(2) contained or referenced in a DMR
consisting of device, process, quality
assurance, packaging and labeling, and
installation, maintenance, and servicing
specifications and procedures; (3)
contained in a DHR and demonstrate the
manufacture of each unit, lot, or batch
of product in conformance with DMR
and regulatory requirements, include
manufacturing and distribution dates,
quantities, acceptance documents,
labels and labeling, control numbers;
and (4) contained in a quality system
record (QSR), consisting of references,
documents, procedures, and activities
not specific to particular devices.
Sections 820.198(a) through (c) and
820.200(a) through (d), respectively,
require the establishment, maintenance,
and/or documentation of the following
topics: (1) Complaint files and
procedures for receiving, reviewing and
evaluating complaints; (2) complaint
investigation records identifying the
device, complainant, and relationship of
the device to the incident; (3) complaint
records that are reasonably accessible to
the manufacturing site or at prescribed
sites; (4) procedures for performing and
verifying that device servicing
requirements are met and that service
reports involving complaints are
processed as complaints; and (5) service
reports that record the device, service
activity, and test and inspection data.
Section 820.250 requires the
establishment and maintenance of
procedures to identify valid statistical
techniques necessary to verify process
and product acceptability; and sampling
plans, when used, which are written
and based on valid statistical rationale;
and procedures for ensuring adequate
sampling methods. The CGMP/QS
regulation amends and revises the
CGMP requirements for medical devices
set out under part 820. The regulation
adds design and purchasing controls;
modifies previous critical device
requirements; revises previous
validation and other requirements; and
harmonizes device CGMP requirements
with QS specifications in the
international standard ‘‘ISO 9001:
Quality Systems Model for Quality
Assurance in Design/Development,
Production, Installation, and Servicing.’’
VerDate Mar<15>2010
16:45 Oct 15, 2010
Jkt 223001
The rule does not apply to
manufacturers of components or parts of
finished devices, nor to manufacturers
of human blood and blood components
subject to 21 CFR part 606. With respect
to devices classified in class I, design
control requirements apply only to class
I devices listed in § 820.30(a)(2) of the
regulation. The rule imposes burden
upon: (1) Finished device manufacturer
firms, which are subject to all
recordkeeping requirements; (2)
finished device contract manufacturers,
specification developers; and (3)
repacker, relabelers, and contract
sterilizer firms, which are subject only
to requirements applicable to their
activities. In addition, remanufacturers
of hospital single-use devices (SUDs)
will now be considered to have the
same requirements as manufacturers in
regard to this regulation. The
establishment, maintenance and/or
documentation of procedures, records,
and data required by this regulation will
assist FDA in determining whether
firms are in compliance with CGMP
requirements, which are intended to
ensure that devices meet their design,
production, labeling, installation, and
servicing specifications and, thus are
safe, effective and suitable for their
intended purpose. In particular,
compliance with CGMP design control
requirements should decrease the
number of design-related device failures
that have resulted in deaths and serious
injuries.
The CGMP/QS regulation applies to
approximately 8,924 respondents. These
recordkeepers consist of 8,945 original
respondents and an estimated 18
hospitals that remanufacture or reuse
SUDs. They include manufacturers,
subject to all requirements and contract
manufacturers, specification developers,
repackers, relabelers, and contract
sterilizers, subject only to requirements
applicable to their activities. Hospital
remanufacturers of SUDs are now
defined to be manufacturers under
guidelines issued by FDA’s Center for
Devices and Radiological Health
(CDRH), Office of Surveillance and
Biometrics. Respondents to this
collection have no reporting activities,
but must make required records
available for review or copying during
FDA inspection. The regulation contains
additional recordkeeping requirements
in such areas as design control,
purchasing, installation, and
information relating to there
manufacture of SUDs. The estimates for
this burden are derived from those
incremental tasks that were determined
when the new CGMP/QS regulation
became final as well as those carryover
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
requirements. The carryover
requirements are based on decisions
made by the agency on July 16, 1992,
under OMB Control Number 0910–0073,
which still provides valid base line data.
Explanation of Recordkeeping Burden
Estimate
FDA estimates respondents will have
a total annual recordkeeping burden of
approximately 3,105,552 hours. This
figure also consists of approximately
143,052 hours spent on a startup basis
by 734 new firms.
Burden (labor) hour and cost
estimates were originally developed
under FDA contract by Eastern Research
Group, Inc. (ERG), in 1996 when the
CGMP/QS regulation became final.
Additional factors considered in
deriving estimates included the
following:
• Establishment type: Query has been
made of CDRH’s registration/listing
databank and the current count was
7,748 domestic firms subject to CGMPs.
It was also calculated that each year, the
number of new domestic firms subject
to CGMPs is 734. The average amount
of firms therefore subject to CGMPs over
the 3 years is therefore 8,924 and this
figure has been used to calculate the
total burden. Because the total number
of registered firms is not static, the
number of respondents will fluctuate
from year to year resulting in slight
changes to the overall burden.
• During the last report it was
estimated that this number was 8,963.
When the last set of numbers was
calculated, FDA was still using a paper
based system to register and list firms.
On October 1, 2007, FDA switched to an
electronic system for registration and
listing. Also at that time the Food and
Drug Administration Amendments Act
of 2007 instituted an establishment
registration fee for some types of
facilities. FDA believes that during the
fiscal year 2008 annual registration
cycle, establishments that had
previously registered but were not
required to do so, removed themselves
from inventory of active establishments.
FDA believes that the current figures
reported by the electronic system more
accurately reflect the inventory of
registered establishments.
• Potentially affected establishments:
Except for manufacturers, not every type
of firm is subject to every CGMP/QS
requirement. For example, all are
subject to Quality Policy (§ 820.20(a)),
Document Control (§ 820.40), and other
requirements, whereas only
manufacturers and specification
developers are subject to subpart C,
Design Controls. The type of firm
E:\FR\FM\18OCN1.SGM
18OCN1
63837
Federal Register / Vol. 75, No. 200 / Monday, October 18, 2010 / Notices
subject to each requirement was
identified by the ERG.
• FDA estimated the burden hours
(and costs) for the previous CGMP
regulation in 1992. That estimate was
submitted to OMB on May 4, 1992,
under OMB Paperwork Reduction Act
Control Number 0910–0073. It was
approved by OMB on July 16, 1992, and
expired on June 30, 1995. The
methodology used is different than that
used by ERG in estimating incremental
tasks when the new CGMP/QS became
final rule. Nevertheless, the agency
believes its 1992 estimate adequately
represents labor hours (and costs)
needed to comply with previous CGMP
requirements carried over into the new
CGMP/QS regulation. The 1992 estimate
used 9,289 respondents (rather than
8,924 respondents), which compensates
for differences in methodology.
In the Federal Register of June 24,
2010 (75 FR 36092), FDA published a
60-day notice requesting public
comment on the proposed collection of
information. FDA received two
comments, however only one was
regarding the information collection.
One part of the comment questioned a
technical reference found within the 60day notice, stating not that the reference
was incorrect, but that it may be
somewhat misleading since the
reference is updated on a regular basis
and this was not communicated in the
notice. While the commenter is correct
that ISO 9001 is on version 2008 and
ISO/DIS 13485 is on version 2003, the
standard ISO 9001 and ISO/DIS 13485
are referenced because they are the
standard regardless of version.
Another part of the comment
maintains that the term ‘‘collect’’ is
misleading as it pertains to
recordkeeping requirements because
relevant documents are only submitted
if requested; however, the comment
agrees that the information collection is
necessary. Under the PRA regulations,
records retention is considered
‘‘information collection,’’ as defined by
the PRA 5 CFR 1320.3
A third part of the comment stated
that it was not clear to whom the
regulations applied based on the
statement, ‘‘[e]xcept for manufacturers,
not every type of firm is subject to every
CGMP/QS requirement.’’ FDA believes
the scope of the regulations found at
part 820.1 makes it clear to whom the
requirements are applicable.
The commenter questioned the
validity and availability of a study that
was conducted by the ERG in 1996,
claiming that without benefit of the
study itself, comments regarding burden
estimates were too difficult to make. As
a basis for its burden estimates, the
agency relied in part on certain pieces
of information found in the 1996 study
and recommends that FDA make this
document part of the docket. The study
was submitted to OMB as part of the
original PRA approval and is part of the
Federal docket.
The commenter states that FDA
assumes that the burden for each firm is
the same, i.e., each of the 8,924 firms
has exactly the same burden. The
flexibility of the system suggests that the
‘‘one size fits all’’ approach in the
Federal Register is not appropriate. The
PRA burden placed on the 8,924 firms
is an average burden on respondents.
The commenter believes that the
estimates the agency provides are too
low, but does not offer an alternative
methodology for estimating that the
agency may review. The comment goes
on to suggest, however, that a new
analysis similar to the 1996 study be
conducted and serve as the basis for
future burden estimates because our
estimates have not changed in several
years. While FDA agrees that additional
analysis is always helpful in
determining burden, the agency does
perform ongoing reviews of the burden
associated with PRA burden as required
under the PRA for purposes of
evaluating burden associated with its
information collection requests, and has
done so for purposes of renewing these
CGMP/QS regulations.
Finally, the commenter suggests that
the agency’s regulation regarding
electronic signatures found at part 11
(21 CFR part 11) is overly cumbersome
to many firms. Part 11 is a separate
regulation from part 820, and it is only
mentioned for reference purposes in the
preamble. The record keeping for part
11 is not within the scope of this
paperwork analysis.
Also, CDRH is proactive in ensuring
that the medical device industry and
other affected individuals are made
aware of on-going issues relating to the
CGMP/QS regulations. FDA’s Medical
Device GMP/QS experts have
participated in numerous conferences
and seminars relating to the CGMP/QS
regulatory requirements. During these
sessions, our GMP/QS experts share
information through speeches and panel
discussions that provide a forum for
open discussion. During these
discussions guidance and direction is
often given to the audience to help them
understand their regulatory
responsibilities under the GMP/QS
regulation. In addition, issues are
sometimes identified by the audience
that provides the agency areas that we
may need to clarify to affected
individuals.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1
Number of
recordkeepers
mstockstill on DSKH9S0YB1PROD with NOTICES
CFR section
820.20(a) ..........................................................
820.20(b) ..........................................................
820.20(c) ..........................................................
820.20(d) ..........................................................
820.20(e) ..........................................................
820.22 ..............................................................
820.25(b) ..........................................................
820.30(a)(1) .....................................................
820.30(b) ..........................................................
820.30(c) ..........................................................
820.30(d) ..........................................................
820.30(e) ..........................................................
820.30(f) ...........................................................
820.30(g) ..........................................................
820.30(h) ..........................................................
820.30(i) ...........................................................
820.30(j) ...........................................................
VerDate Mar<15>2010
16:45 Oct 15, 2010
Jkt 223001
PO 00000
Annual
frequency per
recordkeeping
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
Frm 00040
Fmt 4703
Total annual
records
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Sfmt 4703
Hours per
record
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
E:\FR\FM\18OCN1.SGM
Total hours
7
4
6
10
10
33
13
2
6
2
2
23
37
37
3
17
3
18OCN1
62,468
35,696
53,544
89,240
89,240
294,492
116,012
17,848
53,544
17,848
17,848
205,252
330,188
330,188
26,772
151,708
26,772
63838
Federal Register / Vol. 75, No. 200 / Monday, October 18, 2010 / Notices
TABLE 1—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1—Continued
Number of
recordkeepers
CFR section
Annual
frequency per
recordkeeping
Total annual
records
Hours per
record
Total hours
820.40 ..............................................................
820.40(a) and (b) .............................................
820.50(a)(1) through (a)(3) ..............................
820.50(b) ..........................................................
820.6 ................................................................
820.65 ..............................................................
820.70(a)(1) through (a)(5) ..............................
820.70(b) and (c) .............................................
820.70(d) ..........................................................
820.70(e) ..........................................................
820.70(g)(1) through (g)(3) ..............................
820.70(h) ..........................................................
820.70(i) ...........................................................
820.72(a) ..........................................................
820.72(b)(1) and (b)(2) ....................................
820.75(a) ..........................................................
820.75(b) ..........................................................
820.75(c) ..........................................................
820.80(a) through (e) .......................................
820.86 ..............................................................
820.90(a) ..........................................................
820.90(b)(1) and (b)(2) ....................................
820.100(a)(1) through (a)(7) ............................
820.100(b) ........................................................
820.120(b) ........................................................
820.120(d) ........................................................
820.130 ............................................................
820.140 ............................................................
820.150(a) and (b) ...........................................
820.160(a) and (b) ...........................................
820.170(a) and (b) ...........................................
820.180(b) and (c) ...........................................
820.181(a) through (e) .....................................
820.184(a) through (f) ......................................
820.186 ............................................................
820.198(a) through (c) .....................................
820.200(a) and (d) ...........................................
820.25 ..............................................................
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
8,924
9
2
22
6
1
1
2
2
3
2
1
2
8
5
1
3
1
1
5
1
5
5
12
1
1
1
1
6
6
1
2
2
1
1
1
5
3
1
80,316
17,848
196,328
53,544
8,924
8,924
17,848
17,848
26,772
17,848
8,924
17,848
71,392
44,620
8,924
26,772
8,924
8,924
44,620
8,924
44,620
44,620
107,088
8,924
8,924
8,924
8,924
53,544
53,544
8,924
17,848
17,848
8,924
8,924
8,924
44,620
26,772
8,924
Totals ........................................................
............................
............................
............................
............................
3,105,552
1 There
are no capital or operating and maintenance costs associated with this collection of information.
Dated: October 12, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–26102 Filed 10–15–10; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
mstockstill on DSKH9S0YB1PROD with NOTICES
[Docket No. FDA–2010–N–0344]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Testing
Communications on Medical Devices
and Radiation-Emitting Products
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
VerDate Mar<15>2010
16:45 Oct 15, 2010
Jkt 223001
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by November
17, 2010.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or e-mailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–NEW and
the title ‘‘Testing Communications on
Medical Devices and Radiation-Emitting
Products.’’ Also include the FDA docket
SUMMARY:
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Daniel Gittleson, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
5156, Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
Testing Communications on Medical
Devices and Radiation-Emitting
Products—(OMB Control Number 0910–
NEW)
FDA is authorized by section
1003(d)(2)(D) of the Federal Food, Drug,
and Cosmetic Act (21 U.S.C.
393(d)(2)(D)) to conduct educational
and public information programs
E:\FR\FM\18OCN1.SGM
18OCN1
Agencies
[Federal Register Volume 75, Number 200 (Monday, October 18, 2010)]
[Notices]
[Pages 63834-63838]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-26102]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0273]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Current Good
Manufacturing Practice Quality System Regulations
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by
November 17, 2010.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or e-mailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0073.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Daniel Gittleson, Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850, 301-796-5156,
Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Medical Devices: Current Good Manufacturing Practice Quality System
Regulations--21
CFR Part 820 (OMB Control Number 0910-0073)--Extension
Under section 520(f) of the Federal Food, Drug, and Cosmetic Act
(the FD&C act) (21 U.S.C. 360j(f)), the Secretary of the Department of
Health and Human Services has the authority to prescribe regulations
requiring that the methods used in, and the facilities and controls
used for, the manufacture, preproduction design validation (including a
process to assess the performance of a device but not including an
evaluation of the safety and effectiveness of a device), packing,
storage, and installation of a device conform to current good
manufacturing practice (CGMP), as described in such regulations, to
assure that the device will be safe and effective and otherwise in
compliance with the act.
The CGMP/quality system (QS) regulation implementing authority
provided by this statutory provision is found under part 820 (21 CFR
part 820) and sets forth basic CGMP requirements governing the design,
manufacture, packing, labeling, storage, installation, and servicing of
all finished medical devices intended for human use. The authority for
this regulation is covered under sections 501, 502, 510, 513, 514, 515,
518, 519, 520, 522, 701, 704, 801, and 803 of the FD&C act (21 U.S.C.
351, 352, 360, 360c, 360d, 360e, 360h, 360i, 360j, 360l, 371, 374, 381,
and 383). The CGMP/QS regulation includes requirements for purchasing
and service controls, clarifies recordkeeping requirements for device
failure and complaint investigations, clarifies requirements for
verifying/validating production processes and process or product
changes, and clarifies
[[Page 63835]]
requirements for product acceptance activities quality data evaluations
and corrections of nonconforming product/quality problems.
Requirements are compatible with specifications in the
international standards ``ISO 9001: Quality Systems Model for Quality
Assurance in Design/Development, Production, Installation, and
Servicing.'' The CGMP/QS information collections will assist FDA
inspections of manufacturers for compliance with QS requirements
encompassing design, production, installation, and servicing processes.
Section 820.20(a) through (e) requires management with executive
responsibility to establish, maintain, and/or review the following
topics: (1) The quality policy, (2) the organizational structure, (3)
the quality plan, and (4) the quality system procedures of the
organization.
Section 820.22 requires the conduct and documentation of QS audits
and re-audits. Section 820.25(b) requires the establishment of
procedures to identify training needs and documentation of such
training.
Section 820.30(a)(1) and (b) through (j), requires in respective
order, the establishment, maintenance, and/or documentation of the
following topics: (1) Procedures to control design of class III and
class II devices and certain class I devices as listed therein; (2)
plans for design and development activities and updates; (3) procedures
identifying, documenting, and approving design input requirements; (4)
procedures defining design output, including acceptance criteria, and
documentation of approved records; (5) procedures for formal review of
design results and documentation of results in the design history file
(DHF); (6) procedures for verifying device design and documentation of
results and approvals in the DHF; (7) procedures for validating device
design, including documentation of results in the DHF; (8) procedures
for translating device design into production specifications; (9)
procedures for documenting, verifying, and validating approved design
changes before implementation of changes; and (10) the records and
references constituting the DHF for each type of device.
Section 820.40 requires manufacturers to establish and maintain
procedures controlling approval and distribution of required documents
and document changes.
Section 820.40(a) and (b) requires the establishment and
maintenance of procedures for the review, approval, issuance, and
documentation of required records (documents) and changes to those
records.
Section 820.50(a)(1), (a)(2), (a)(3), and (b) requires the
establishment and maintenance of procedures and requirements to ensure
service and product quality, records of acceptable suppliers, and
purchasing data describing specified requirements for products and
services.
Sections 820.60 and 820.65 require, respectively, the establishment
and maintenance of procedures for identifying all products from receipt
to distribution and for using control numbers to track surgical
implants and life-sustaining or supporting devices and their
components.
Section 820.70(a)(1) through (a)(5), (b) through (e), (g)(1)
through (g)(3), (h), and (i) requires the establishment, maintenance,
and/or documentation of the following topics: (1) Process control
procedures; (2) procedures for verifying or validating changes to
specification, method, process, or procedure; (3) procedures to control
environmental conditions and inspection result records; (4)
requirements for personnel hygiene; (5) procedures for preventing
contamination of equipment and products; (6) equipment adjustment,
cleaning, and maintenance schedules; (7) equipment inspection records;
(8) equipment tolerance postings, procedures for utilizing
manufacturing materials expected to have an adverse effect on product
quality; and (9) validation protocols and validation records for
computer software and software changes.
Sections 820.72(a), (b)(1), and (b)(2) and 820.75(a) through (c)
require, respectively, the establishment, maintenance, and/or
documentation of the following topics: (1) Equipment calibration and
inspection procedures; (2) national, international or in-house
calibration standards; (3) records that identify calibrated equipment
and next calibration dates; (4) validation procedures and validation
results for processes not verifiable by inspections and tests; (5)
procedures for keeping validated processes within specified limits; (6)
records for monitoring and controlling validated processes; and (7)
records of the results of revalidation where necessitated by process
changes or deviations.
Sections 820.80(a) through (e) and 820.86, respectively, require
the establishment, maintenance, and/or documentation of the following
topics: (1) Procedures for incoming acceptance by inspection, test, or
other verification; (2) procedures for ensuring that in process
products meet specified requirements and the control of product until
inspection and tests are completed; (3) procedures for, and records
that show, incoming acceptance or rejection is conducted by
inspections, tests or other verifications; (4) procedures for, and
records that show, finished devices meet acceptance criteria and are
not distributed until device master record (DMR) activities are
completed; (5) records in the device history record (DHR) showing
acceptance dates, results, and equipment used; and (6) the acceptance/
rejection identification of products from receipt to installation and
servicing.
Sections 820.90(a), (b)(1), and (b)(2) and 820.100 require,
respectively, the establishment, maintenance and/or documentation of
the following topics: (1) Procedures for identifying, recording,
evaluating, and disposing of nonconforming product; (2) procedures for
reviewing and recording concessions made for, and disposition of,
nonconforming product; (3) procedures for reworking products,
evaluating possible adverse rework effect and recording results in the
DHR; (4) procedures and requirements for corrective and preventive
actions, including analysis, investigation, identification and review
of data, records, causes, and results; and (5) records for all
corrective and preventive action activities.
Section 820.100(a)(1) through (a)(7) states that procedures and
requirements shall be established and maintained for corrective/
preventive actions, including the following: (1) Analysis of data from
process, work, quality, servicing records; investigation of
nonconformance causes; (2) identification of corrections and their
effectiveness; (3) recording of changes made; and (4) appropriate
distribution and managerial review of corrective and preventive action
information. Section 820.120 states that manufacturers shall establish/
maintain procedures to control labeling storage/application; and
examination/release for storage and use, and document those procedures.
Sections 820.120(b) and (d), 820.130, 820.140, 820.150(a) and (b),
820.160(a) and (b), and 820.170(a) and (b), respectively, require the
establishment, maintenance, and/or documentation of following topics:
(1) Procedures for controlling and recording the storage, examination,
release, and use of labeling; (2) the filing of labels/labeling used in
the DHR; (3) procedures for controlling product storage areas and
receipt/dispatch authorizations; (4) procedures controlling the release
of products for distribution; (5) distribution records that identify
consignee, product, date, and control
[[Page 63836]]
numbers; and (6) instructions, inspection and test procedures that are
made available, and the recording of results for devices requiring
installation.
Sections 820.180(b) and (c), 820.181(a) through (e), 820.184(a)
through (f), and 820.186 require, respectively, the maintenance of
records that are: (1) Retained at prescribed site(s), made readily
available and accessible to FDA and retained for the device's life
expectancy or for 2 years; (2) contained or referenced in a DMR
consisting of device, process, quality assurance, packaging and
labeling, and installation, maintenance, and servicing specifications
and procedures; (3) contained in a DHR and demonstrate the manufacture
of each unit, lot, or batch of product in conformance with DMR and
regulatory requirements, include manufacturing and distribution dates,
quantities, acceptance documents, labels and labeling, control numbers;
and (4) contained in a quality system record (QSR), consisting of
references, documents, procedures, and activities not specific to
particular devices.
Sections 820.198(a) through (c) and 820.200(a) through (d),
respectively, require the establishment, maintenance, and/or
documentation of the following topics: (1) Complaint files and
procedures for receiving, reviewing and evaluating complaints; (2)
complaint investigation records identifying the device, complainant,
and relationship of the device to the incident; (3) complaint records
that are reasonably accessible to the manufacturing site or at
prescribed sites; (4) procedures for performing and verifying that
device servicing requirements are met and that service reports
involving complaints are processed as complaints; and (5) service
reports that record the device, service activity, and test and
inspection data. Section 820.250 requires the establishment and
maintenance of procedures to identify valid statistical techniques
necessary to verify process and product acceptability; and sampling
plans, when used, which are written and based on valid statistical
rationale; and procedures for ensuring adequate sampling methods. The
CGMP/QS regulation amends and revises the CGMP requirements for medical
devices set out under part 820. The regulation adds design and
purchasing controls; modifies previous critical device requirements;
revises previous validation and other requirements; and harmonizes
device CGMP requirements with QS specifications in the international
standard ``ISO 9001: Quality Systems Model for Quality Assurance in
Design/Development, Production, Installation, and Servicing.'' The rule
does not apply to manufacturers of components or parts of finished
devices, nor to manufacturers of human blood and blood components
subject to 21 CFR part 606. With respect to devices classified in class
I, design control requirements apply only to class I devices listed in
Sec. 820.30(a)(2) of the regulation. The rule imposes burden upon: (1)
Finished device manufacturer firms, which are subject to all
recordkeeping requirements; (2) finished device contract manufacturers,
specification developers; and (3) repacker, relabelers, and contract
sterilizer firms, which are subject only to requirements applicable to
their activities. In addition, remanufacturers of hospital single-use
devices (SUDs) will now be considered to have the same requirements as
manufacturers in regard to this regulation. The establishment,
maintenance and/or documentation of procedures, records, and data
required by this regulation will assist FDA in determining whether
firms are in compliance with CGMP requirements, which are intended to
ensure that devices meet their design, production, labeling,
installation, and servicing specifications and, thus are safe,
effective and suitable for their intended purpose. In particular,
compliance with CGMP design control requirements should decrease the
number of design-related device failures that have resulted in deaths
and serious injuries.
The CGMP/QS regulation applies to approximately 8,924 respondents.
These recordkeepers consist of 8,945 original respondents and an
estimated 18 hospitals that remanufacture or reuse SUDs. They include
manufacturers, subject to all requirements and contract manufacturers,
specification developers, repackers, relabelers, and contract
sterilizers, subject only to requirements applicable to their
activities. Hospital remanufacturers of SUDs are now defined to be
manufacturers under guidelines issued by FDA's Center for Devices and
Radiological Health (CDRH), Office of Surveillance and Biometrics.
Respondents to this collection have no reporting activities, but must
make required records available for review or copying during FDA
inspection. The regulation contains additional recordkeeping
requirements in such areas as design control, purchasing, installation,
and information relating to there manufacture of SUDs. The estimates
for this burden are derived from those incremental tasks that were
determined when the new CGMP/QS regulation became final as well as
those carryover requirements. The carryover requirements are based on
decisions made by the agency on July 16, 1992, under OMB Control Number
0910-0073, which still provides valid base line data.
Explanation of Recordkeeping Burden Estimate
FDA estimates respondents will have a total annual recordkeeping
burden of approximately 3,105,552 hours. This figure also consists of
approximately 143,052 hours spent on a startup basis by 734 new firms.
Burden (labor) hour and cost estimates were originally developed
under FDA contract by Eastern Research Group, Inc. (ERG), in 1996 when
the CGMP/QS regulation became final. Additional factors considered in
deriving estimates included the following:
Establishment type: Query has been made of CDRH's
registration/listing databank and the current count was 7,748 domestic
firms subject to CGMPs. It was also calculated that each year, the
number of new domestic firms subject to CGMPs is 734. The average
amount of firms therefore subject to CGMPs over the 3 years is
therefore 8,924 and this figure has been used to calculate the total
burden. Because the total number of registered firms is not static, the
number of respondents will fluctuate from year to year resulting in
slight changes to the overall burden.
During the last report it was estimated that this number
was 8,963. When the last set of numbers was calculated, FDA was still
using a paper based system to register and list firms. On October 1,
2007, FDA switched to an electronic system for registration and
listing. Also at that time the Food and Drug Administration Amendments
Act of 2007 instituted an establishment registration fee for some types
of facilities. FDA believes that during the fiscal year 2008 annual
registration cycle, establishments that had previously registered but
were not required to do so, removed themselves from inventory of active
establishments. FDA believes that the current figures reported by the
electronic system more accurately reflect the inventory of registered
establishments.
Potentially affected establishments: Except for
manufacturers, not every type of firm is subject to every CGMP/QS
requirement. For example, all are subject to Quality Policy (Sec.
820.20(a)), Document Control (Sec. 820.40), and other requirements,
whereas only manufacturers and specification developers are subject to
subpart C, Design Controls. The type of firm
[[Page 63837]]
subject to each requirement was identified by the ERG.
FDA estimated the burden hours (and costs) for the
previous CGMP regulation in 1992. That estimate was submitted to OMB on
May 4, 1992, under OMB Paperwork Reduction Act Control Number 0910-
0073. It was approved by OMB on July 16, 1992, and expired on June 30,
1995. The methodology used is different than that used by ERG in
estimating incremental tasks when the new CGMP/QS became final rule.
Nevertheless, the agency believes its 1992 estimate adequately
represents labor hours (and costs) needed to comply with previous CGMP
requirements carried over into the new CGMP/QS regulation. The 1992
estimate used 9,289 respondents (rather than 8,924 respondents), which
compensates for differences in methodology.
In the Federal Register of June 24, 2010 (75 FR 36092), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. FDA received two comments, however only one
was regarding the information collection. One part of the comment
questioned a technical reference found within the 60-day notice,
stating not that the reference was incorrect, but that it may be
somewhat misleading since the reference is updated on a regular basis
and this was not communicated in the notice. While the commenter is
correct that ISO 9001 is on version 2008 and ISO/DIS 13485 is on
version 2003, the standard ISO 9001 and ISO/DIS 13485 are referenced
because they are the standard regardless of version.
Another part of the comment maintains that the term ``collect'' is
misleading as it pertains to recordkeeping requirements because
relevant documents are only submitted if requested; however, the
comment agrees that the information collection is necessary. Under the
PRA regulations, records retention is considered ``information
collection,'' as defined by the PRA 5 CFR 1320.3
A third part of the comment stated that it was not clear to whom
the regulations applied based on the statement, ``[e]xcept for
manufacturers, not every type of firm is subject to every CGMP/QS
requirement.'' FDA believes the scope of the regulations found at part
820.1 makes it clear to whom the requirements are applicable.
The commenter questioned the validity and availability of a study
that was conducted by the ERG in 1996, claiming that without benefit of
the study itself, comments regarding burden estimates were too
difficult to make. As a basis for its burden estimates, the agency
relied in part on certain pieces of information found in the 1996 study
and recommends that FDA make this document part of the docket. The
study was submitted to OMB as part of the original PRA approval and is
part of the Federal docket.
The commenter states that FDA assumes that the burden for each firm
is the same, i.e., each of the 8,924 firms has exactly the same burden.
The flexibility of the system suggests that the ``one size fits all''
approach in the Federal Register is not appropriate. The PRA burden
placed on the 8,924 firms is an average burden on respondents.
The commenter believes that the estimates the agency provides are
too low, but does not offer an alternative methodology for estimating
that the agency may review. The comment goes on to suggest, however,
that a new analysis similar to the 1996 study be conducted and serve as
the basis for future burden estimates because our estimates have not
changed in several years. While FDA agrees that additional analysis is
always helpful in determining burden, the agency does perform ongoing
reviews of the burden associated with PRA burden as required under the
PRA for purposes of evaluating burden associated with its information
collection requests, and has done so for purposes of renewing these
CGMP/QS regulations.
Finally, the commenter suggests that the agency's regulation
regarding electronic signatures found at part 11 (21 CFR part 11) is
overly cumbersome to many firms. Part 11 is a separate regulation from
part 820, and it is only mentioned for reference purposes in the
preamble. The record keeping for part 11 is not within the scope of
this paperwork analysis.
Also, CDRH is proactive in ensuring that the medical device
industry and other affected individuals are made aware of on-going
issues relating to the CGMP/QS regulations. FDA's Medical Device GMP/QS
experts have participated in numerous conferences and seminars relating
to the CGMP/QS regulatory requirements. During these sessions, our GMP/
QS experts share information through speeches and panel discussions
that provide a forum for open discussion. During these discussions
guidance and direction is often given to the audience to help them
understand their regulatory responsibilities under the GMP/QS
regulation. In addition, issues are sometimes identified by the
audience that provides the agency areas that we may need to clarify to
affected individuals.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Recordkeeping Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Annual
CFR section Number of frequency per Total annual Hours per Total hours
recordkeepers recordkeeping records record
--------------------------------------------------------------------------------------------------------------------------------------------------------
820.20(a)..................................................... 8,924 1 8,924 7 62,468
820.20(b)..................................................... 8,924 1 8,924 4 35,696
820.20(c)..................................................... 8,924 1 8,924 6 53,544
820.20(d)..................................................... 8,924 1 8,924 10 89,240
820.20(e)..................................................... 8,924 1 8,924 10 89,240
820.22........................................................ 8,924 1 8,924 33 294,492
820.25(b)..................................................... 8,924 1 8,924 13 116,012
820.30(a)(1).................................................. 8,924 1 8,924 2 17,848
820.30(b)..................................................... 8,924 1 8,924 6 53,544
820.30(c)..................................................... 8,924 1 8,924 2 17,848
820.30(d)..................................................... 8,924 1 8,924 2 17,848
820.30(e)..................................................... 8,924 1 8,924 23 205,252
820.30(f)..................................................... 8,924 1 8,924 37 330,188
820.30(g)..................................................... 8,924 1 8,924 37 330,188
820.30(h)..................................................... 8,924 1 8,924 3 26,772
820.30(i)..................................................... 8,924 1 8,924 17 151,708
820.30(j)..................................................... 8,924 1 8,924 3 26,772
[[Page 63838]]
820.40........................................................ 8,924 1 8,924 9 80,316
820.40(a) and (b)............................................. 8,924 1 8,924 2 17,848
820.50(a)(1) through (a)(3)................................... 8,924 1 8,924 22 196,328
820.50(b)..................................................... 8,924 1 8,924 6 53,544
820.6......................................................... 8,924 1 8,924 1 8,924
820.65........................................................ 8,924 1 8,924 1 8,924
820.70(a)(1) through (a)(5)................................... 8,924 1 8,924 2 17,848
820.70(b) and (c)............................................. 8,924 1 8,924 2 17,848
820.70(d)..................................................... 8,924 1 8,924 3 26,772
820.70(e)..................................................... 8,924 1 8,924 2 17,848
820.70(g)(1) through (g)(3)................................... 8,924 1 8,924 1 8,924
820.70(h)..................................................... 8,924 1 8,924 2 17,848
820.70(i)..................................................... 8,924 1 8,924 8 71,392
820.72(a)..................................................... 8,924 1 8,924 5 44,620
820.72(b)(1) and (b)(2)....................................... 8,924 1 8,924 1 8,924
820.75(a)..................................................... 8,924 1 8,924 3 26,772
820.75(b)..................................................... 8,924 1 8,924 1 8,924
820.75(c)..................................................... 8,924 1 8,924 1 8,924
820.80(a) through (e)......................................... 8,924 1 8,924 5 44,620
820.86........................................................ 8,924 1 8,924 1 8,924
820.90(a)..................................................... 8,924 1 8,924 5 44,620
820.90(b)(1) and (b)(2)....................................... 8,924 1 8,924 5 44,620
820.100(a)(1) through (a)(7).................................. 8,924 1 8,924 12 107,088
820.100(b).................................................... 8,924 1 8,924 1 8,924
820.120(b).................................................... 8,924 1 8,924 1 8,924
820.120(d).................................................... 8,924 1 8,924 1 8,924
820.130....................................................... 8,924 1 8,924 1 8,924
820.140....................................................... 8,924 1 8,924 6 53,544
820.150(a) and (b)............................................ 8,924 1 8,924 6 53,544
820.160(a) and (b)............................................ 8,924 1 8,924 1 8,924
820.170(a) and (b)............................................ 8,924 1 8,924 2 17,848
820.180(b) and (c)............................................ 8,924 1 8,924 2 17,848
820.181(a) through (e)........................................ 8,924 1 8,924 1 8,924
820.184(a) through (f)........................................ 8,924 1 8,924 1 8,924
820.186....................................................... 8,924 1 8,924 1 8,924
820.198(a) through (c)........................................ 8,924 1 8,924 5 44,620
820.200(a) and (d)............................................ 8,924 1 8,924 3 26,772
820.25........................................................ 8,924 1 8,924 1 8,924
-----------------------------------------------------------------------------------------
Totals.................................................... ................ ................ ................ ................ 3,105,552
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital or operating and maintenance costs associated with this collection of information.
Dated: October 12, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-26102 Filed 10-15-10; 8:45 am]
BILLING CODE 4160-01-P